ATE437652T1 - Verwendung von hmgb1 zur aktivierung dendritischer zellen - Google Patents
Verwendung von hmgb1 zur aktivierung dendritischer zellenInfo
- Publication number
- ATE437652T1 ATE437652T1 AT02775057T AT02775057T ATE437652T1 AT E437652 T1 ATE437652 T1 AT E437652T1 AT 02775057 T AT02775057 T AT 02775057T AT 02775057 T AT02775057 T AT 02775057T AT E437652 T1 ATE437652 T1 AT E437652T1
- Authority
- AT
- Austria
- Prior art keywords
- hmgb1
- dendritic cells
- activate dendritic
- activate
- apc
- Prior art date
Links
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 title abstract 2
- 102000055207 HMGB1 Human genes 0.000 title abstract 2
- 108700010013 HMGB1 Proteins 0.000 title abstract 2
- 101150021904 HMGB1 gene Proteins 0.000 title abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI001986A ITMI20011986A1 (it) | 2001-09-25 | 2001-09-25 | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
| PCT/IB2002/004080 WO2003026691A2 (en) | 2001-09-25 | 2002-09-25 | Use of hmgb1 for the activation of dendritic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE437652T1 true ATE437652T1 (de) | 2009-08-15 |
Family
ID=11448420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02775057T ATE437652T1 (de) | 2001-09-25 | 2002-09-25 | Verwendung von hmgb1 zur aktivierung dendritischer zellen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040242481A1 (de) |
| EP (1) | EP1432441B1 (de) |
| JP (1) | JP2005508913A (de) |
| AT (1) | ATE437652T1 (de) |
| AU (1) | AU2002341266B2 (de) |
| CA (1) | CA2461091A1 (de) |
| DE (1) | DE60233147D1 (de) |
| IT (1) | ITMI20011986A1 (de) |
| WO (1) | WO2003026691A2 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050112121A1 (en) * | 1992-04-30 | 2005-05-26 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| GB0226251D0 (en) * | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
| EP2364998A1 (de) | 2005-06-16 | 2011-09-14 | The Feinstein Institute for Medical Research | Antikörper gegen HMGB1 und Fragmente davon |
| US7829097B2 (en) | 2006-02-06 | 2010-11-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of HMGB1 for protection against ischemia reperfusion injury |
| CA2636788A1 (en) * | 2006-10-30 | 2008-05-08 | Genomix Co., Ltd. | Hmgb protein for use in promoting tissue regeneration |
| US20100173277A1 (en) * | 2007-02-15 | 2010-07-08 | Fukuoka University | Agent for Suppressing Rejection in Organ Transplantation Comprising Anti-HMGB-1 Antibody |
| US20100216977A1 (en) * | 2007-02-15 | 2010-08-26 | Kyushu University, National University Corporation | Therapeutic agent for interstitial pulmonary disease comprising anti-hmgb-1 antibody |
| WO2008099913A1 (ja) | 2007-02-15 | 2008-08-21 | Kumamoto University | ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤 |
| AU2008318357B2 (en) | 2007-11-01 | 2015-01-22 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
| CA2722906A1 (en) * | 2008-04-30 | 2009-11-05 | Genomix Co., Ltd. | Pharmaceutical agent for promoting the functional regeneration of damaged tissue |
| AU2009240888B2 (en) * | 2008-04-30 | 2014-10-09 | Genomix Co., Ltd. | Method for collecting functional cells in vivo with high efficiency |
| EP2301559A4 (de) * | 2008-04-30 | 2012-05-02 | Genomix Co Ltd | Mittel zur rekrutierung von pluripotenten stammzellen aus knochenmark in den peripheren kreislauf |
| RU2016135937A (ru) | 2009-10-28 | 2018-12-11 | Дженомикс Ко., Лтд. | Средства для стимуляции регенерации тканей путем привлечения мезинхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь |
| WO2011091255A1 (en) | 2010-01-21 | 2011-07-28 | The Board Of Trustees Of The University Of Arkansas | Vaccine vectors and methods of enhancing immune responses |
| ES2754240T3 (es) | 2010-03-29 | 2020-04-16 | Univ Southern California | Composiciones y métodos para la retirada de biopelículas |
| MX377650B (es) | 2010-06-09 | 2025-03-11 | Univ Arkansas | Vacuna y métodos para reducir una infección por campylobacter. |
| US20120128701A1 (en) * | 2010-09-09 | 2012-05-24 | Nationwide Children's Hospital, Inc. | Compositions and methods for the removal of biofilms |
| CA2834255C (en) | 2011-04-26 | 2021-11-02 | Genomix Co., Ltd. | Peptide for inducing regeneration of tissue and use thereof |
| WO2012170742A2 (en) * | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
| US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
| KR102146815B1 (ko) | 2012-10-25 | 2020-08-21 | 가부시키가이샤 스템림 | Hmgb1 단편을 이용한 신규 심근경색의 치료법 |
| PL2913059T3 (pl) | 2012-10-25 | 2018-09-28 | Genomix Co., Ltd. | Nowy sposób leczenia urazu rdzenia kręgowego z zastosowaniem fragmentu HMGB1 |
| AR094791A1 (es) | 2013-02-14 | 2015-08-26 | Univ Arkansas | Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria |
| MX376350B (es) | 2013-03-15 | 2025-03-07 | Univ Arkansas | Vectores para vacuna y uso de los mismos para aumentar la respuesta inmune contra patógenos entericos. |
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| US9745366B2 (en) | 2013-09-23 | 2017-08-29 | University Of Southern California | Compositions and methods for the prevention of microbial infections |
| US11248040B2 (en) | 2013-09-26 | 2022-02-15 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
| US10233234B2 (en) | 2014-01-13 | 2019-03-19 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
| WO2017023863A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
| GB201600075D0 (en) | 2016-01-03 | 2016-02-17 | Glaxosmithkline Biolog Sa | Immunogenci composition |
| EP3452069A4 (de) | 2016-05-03 | 2020-02-12 | The Board of Trustees of the University of Arkansas | Hefeimpfstoffvektor mit immunstimulierenden und antigenen polypeptiden und verfahren zur verwendung davon |
| WO2018047917A1 (ja) * | 2016-09-09 | 2018-03-15 | 国立大学法人 東京大学 | Ｈｍｇタンパク質と抗ｃｄ４抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果 |
| MX2019008949A (es) | 2017-01-27 | 2019-10-07 | Stemrim Inc | Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica. |
| US11746136B2 (en) | 2017-03-15 | 2023-09-05 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
| EP3719117A4 (de) | 2017-12-01 | 2021-11-03 | Stemrim Inc. | Ektoderme mesenchymale stammzellen und verfahren zur herstellung davon |
| JPWO2019107530A1 (ja) | 2017-12-01 | 2020-11-26 | 株式会社ステムリム | 炎症性腸疾患の治療薬 |
| JP7386455B2 (ja) | 2018-02-08 | 2023-11-27 | 株式会社ステムリム | 乾癬の治療薬 |
| EP3860718A4 (de) | 2018-10-05 | 2022-08-31 | Research Institute at Nationwide Children's Hospital | Hmgb1-proteinderivate zur entfernung von biofilmen |
| US12304933B2 (en) | 2018-10-05 | 2025-05-20 | StemRIM Inc. | Disease treatment drug based on mesenchymal-stem-cell mobilization |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5214131A (en) * | 1988-05-06 | 1993-05-25 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, modified peptides and production thereof |
| US5091176A (en) * | 1988-11-02 | 1992-02-25 | W. R. Grace & Co.-Conn. | Polymer-modified peptide drugs having enhanced biological and pharmacological activities |
| JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| US5811512A (en) * | 1991-08-22 | 1998-09-22 | The Trustees Of The University Of Pennsylvania | Non-peptide peptidomimetics and related cyclic hexapeptides |
| US5580853A (en) * | 1994-03-22 | 1996-12-03 | New England Deaconess Hospital | Modified polypeptides with increased biological activity |
| US5891418A (en) * | 1995-06-07 | 1999-04-06 | Rhomed Incorporated | Peptide-metal ion pharmaceutical constructs and applications |
| FR2739292B1 (fr) * | 1995-09-28 | 1997-10-31 | Rhone Poulenc Rorer Sa | Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations |
| IT1299583B1 (it) * | 1998-05-19 | 2000-03-16 | Vander Way Limited | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica |
| US6100090A (en) * | 1999-06-25 | 2000-08-08 | Isis Pharmaceuticals Inc. | Antisense inhibition of PI3K p85 expression |
| US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
-
2001
- 2001-09-25 IT IT2001MI001986A patent/ITMI20011986A1/it unknown
-
2002
- 2002-09-25 CA CA002461091A patent/CA2461091A1/en not_active Abandoned
- 2002-09-25 JP JP2003530326A patent/JP2005508913A/ja active Pending
- 2002-09-25 DE DE60233147T patent/DE60233147D1/de not_active Expired - Lifetime
- 2002-09-25 US US10/489,878 patent/US20040242481A1/en not_active Abandoned
- 2002-09-25 AT AT02775057T patent/ATE437652T1/de not_active IP Right Cessation
- 2002-09-25 AU AU2002341266A patent/AU2002341266B2/en not_active Ceased
- 2002-09-25 WO PCT/IB2002/004080 patent/WO2003026691A2/en not_active Ceased
- 2002-09-25 EP EP02775057A patent/EP1432441B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE60233147D1 (de) | 2009-09-10 |
| WO2003026691A2 (en) | 2003-04-03 |
| JP2005508913A (ja) | 2005-04-07 |
| US20040242481A1 (en) | 2004-12-02 |
| ITMI20011986A1 (it) | 2003-03-25 |
| WO2003026691A3 (en) | 2003-05-30 |
| AU2002341266B2 (en) | 2007-11-15 |
| EP1432441A2 (de) | 2004-06-30 |
| EP1432441B1 (de) | 2009-07-29 |
| ITMI20011986A0 (it) | 2001-09-25 |
| CA2461091A1 (en) | 2003-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE437652T1 (de) | Verwendung von hmgb1 zur aktivierung dendritischer zellen | |
| DE59903410D1 (de) | Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung | |
| DE60324430D1 (de) | Methode um rekombinante proteine in cho zellen zu exprimieren | |
| FR10C0025I1 (de) | ||
| ATE277198T1 (de) | Verfahren zur in vitro evolution von proteinfunktionen | |
| ATE323770T1 (de) | Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren | |
| DE69840230D1 (de) | Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren | |
| DE69942459D1 (de) | Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung | |
| EP1601779A4 (de) | Carbonsäurereduktase-polypeptid, dieses codierende nukleotidsequenz und verwendungsverfahren | |
| ATE368688T1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| CY1118782T1 (el) | Επιλογη κυτταρων που εκφραζουν ετερομερη πολυπεπτιδια | |
| CY1109207T1 (el) | Διαδικασια εχινοκανδινης | |
| ATE474926T1 (de) | Verwendung von clya hemolysin fur ausscheidung von fusionprotein | |
| ATE448312T1 (de) | Leitsequenzen zur verwendung bei der produktion von proteinen | |
| CY1117746T1 (el) | Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna | |
| ATE384787T1 (de) | Tripeptidyl-aminopeptidase | |
| DK1344827T3 (da) | Frostbeskyttende proteiner fra basidiomycetes | |
| DE69837475D1 (de) | Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren | |
| DK1145012T3 (da) | Fremgangsmåder og kits til sekventering af polypeptider | |
| DE60332579D1 (de) | Prozess zur Immobilisierung von Polypeptiden über die Carboxylgruppe des C-terminus | |
| ATE391727T1 (de) | Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors | |
| ATE351906T1 (de) | Zur modulation der krebszellenproliferation geeignetes polynukleotid | |
| ATE393213T1 (de) | Dendritische zelle mit alpha-glycosylceramid- derivat und antigen zur verwendung bei der unterdrückung von immunreaktionen | |
| SE9904237D0 (sv) | New compound | |
| MY142798A (en) | Methods for preventing glyconoylation of proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |